Given these considerations, the primary objective of this study was to assess the comparative six-month effects of infliximab (an anti-TNF agent) or vedolizumab (an anti-integrin agent) versus no biologic therapy on presumed hepatic steatosis in IBD patients. This evidence concerns the gene TNF and inflammatory bowel disease.